MarkAgulnikMD

Sarcoma

Professor of Clinical Medicine Vice Chair for Faculty Development, Department of Medicine Section Chief of Sarcoma and Melanoma USC Norris Comprehensive Cancer Center; Keck School of Medicine of USC

Join to view full profile

Dr. Agulnik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Agulnik's full profile

Already have an account?

Office
Keck Medicine of USC
1441 East Lake Avenue, Suite NTT 3440
Los Angeles, CA 90033
Phone+1 323-865-3000

Fax+1 323-865-0061

Summary

Mark Agulnik, MD, is a Sarcoma Oncology specialist in Los Angeles. He received his MD from McGill University. He is a Professor of Medicine at Keck USC. He has a proven track record in Sarcoma Oncology, has been part of numerous clinical trials and has multiple publications. He is the recipient of the Meaninful Use Stage 1 Certification and is recognized as a Super Doctor by SuperDoctors.com.

Education & Training

University of TorontoClinical Research Fellowship, 2004 - 2006
University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 2001 - 2004
Dalhousie UniversityResidency, 1999 - 2001
Dalhousie UniversityInternship, 1998 - 1999
McGill University Faculty of MedicineClass of 1998

Certifications & Licensure

CA State Medical License 2020 - 2026
IL State Medical License 2004 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
The Royal College of Physicians and Surgeons of CanadaInternal Medicine/Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Super Doctor SuperDoctors.com

Clinical Trials

Bevacizumab in Treating Patients With Angiosarcoma Start of enrollment: 2005 Oct 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Everolimus Versus Placebo in Head and Neck Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Completed
Phase 1, Phase 2
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Start of enrollment: 2011 Aug 01
Terminated
Phase 1, Phase 2
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma Start of enrollment: 2011 Nov 03
Completed
Phase 2
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
Completed
Phase 2
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas Start of enrollment: 2013 Mar 06
Completed
Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Start of enrollment: 2014 Jul 01
Completed
Phase 2
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma Start of enrollment: 2014 Jun 13
Completed
Phase 2
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Completed
Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) Start of enrollment: 2017 Aug 15
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

A Phase 1 Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients With Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.
J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik
Clinical Cancer Research. 2024-12-11
1 citations
Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer.
Bhavana Konda, Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar
The Journal of Clinical Endocrinology and Metabolism. 2024-08-12
1 citations
Prices and Trends in FDA-Approved Medications for Sarcomas.
Caleb Hwang, Mark Agulnik, Brian Schulte
Cancers. 2024-04-18

Lectures

A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los AngelesMarch 8th, 2022
Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (Devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, CalifSeptember 27th, 2021
Experts Explain the Staging and Treatment of cSCCNovember 28th, 2019